Rigel Pharmaceuticals, Inc.
NASDAQ:RIGLBiotechnology
-$0.62 today
- Market cap
- $800.84M
- Beta
- 1.18
- P/E (TTM)
- 1.7
- EPS (TTM)
- $19.78
Volume 0.24M
Average 0.36M
RIGL Interest Income
Income earned on cash, deposits, and investments held by the company.
Rigel Pharmaceuticals, Inc.NASDAQ: RIGL
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income grows in line with its trailing trend
Q1 FY2026 interest income of $1.21M rose 103.9% year over year, behind the +105.5% change in trailing-twelve-month interest income. Sequentially, it fell 3.1% from the prior quarter. Over 3 fiscal years it compounded at +75.2% a year.
Context
- Interest income amounted to 1.3% of revenue in FY2025, unchanged from a year earlier.
- Interest income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +103.9% toward the trailing-twelve-month pace of +105.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 3.68M USD
- Year-over-year change
- +76.0%
- 4-year CAGR
- +197.5%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.68M | +76.0% |
| FY2024 | 2024-12-31 | 2.09M | -7.9% |
| FY2023 | 2023-12-31 | 2.27M | +232.2% |
| FY2022 | 2022-12-31 | 684K | +1355.3% |
| FY2021 | 2021-12-31 | 47K | — |
Interest Income vs competitors
How RIGL compares with its peers on the latest reported figures
- RIGL's LTM Mar 2026 interest income of $4.3M is the 6th highest of the 10 companies compared; the peer median is $4.4M.
- Its year-over-year change of +105.5% is the highest of 9, against a peer median of -22.1%.
- Interest income amounts to 1.4% of revenue for RIGL, versus a peer median of 23.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $63.69M | -16.1% | +27.9% | 2.6% | |
| LTM Mar 2026 | $19.73M | -35.4% | +49.8% | — | |
| LTM Aug 2026 | $18.56M | -20.1% | +84.3% | 2.6% | |
| LTM Mar 2026 | $10.16M | -24.2% | +42.5% | 29.2% | |
| LTM Mar 2026 | $4.4M | +17.7% | +49.6% | 8.9% | |
| LTM Mar 2026 | $4.3M | +105.5% | +75.2% | 1.4% | |
| LTM Mar 2026 | $3.66M | -55.5% | -2.5% | — | |
| LTM Mar 2026 | $2.67M | -18.5% | +25.2% | 508.4% | |
| LTM Mar 2026 | $1.84M | -40.4% | +46.2% | 367.5% | |
| LTM Jun 2024 | $1.49M | — | -87.8% | 23.0% | |
| Peer median (excluding RIGL) | $4.4M | -22.1% | +42.5% | 23.0% | |
Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 149.24M | 120.24M | 116.88M | 179.28M | 294.28M |
| Cost of Revenue | 1.08M | 1.75M | 7.11M | 18.65M | 19.62M |
| Gross Profit | 148.15M | 118.49M | 109.77M | 160.63M | 274.66M |
| Gross Margin | 99.3% | 98.5% | 93.9% | 89.6% | 93.3% |
| Research & Development | 65.24M | 60.27M | 24.52M | 23.38M | 33.3M |
| Selling, General & Admin | 91.89M | 112.45M | 105.74M | 113.06M | 115.9M |
| Operating Expenses | 160.65M | 174.04M | 130.26M | 136.44M | 149.2M |
| Depreciation & Amortization | 1.16M | 998K | 1.24M | 2.23M | 2.42M |
| EBITDA | (11.29M) | (53.87M) | (16.98M) | 28.51M | 131.56M |
| EBITDA Margin | -7.6% | -44.8% | -14.5% | 15.9% | 44.7% |
| Operating Income | (12.5M) | (55.55M) | (20.49M) | 24.19M | 125.47M |
| Operating Margin | -8.4% | -46.2% | -17.5% | 13.5% | 42.6% |
| Interest Income | 47K | 684K | 2.27M | 2.09M | 3.68M |
| Interest Expense | 4.86M | 3.71M | 6.87M | 7.92M | 7.32M |
| Other Income / Expenses | (4.81M) | (3.02M) | (4.6M) | (5.83M) | (3.64M) |
| Income Before Tax | (17.31M) | (58.57M) | (25.09M) | 18.37M | 121.83M |
| Pre-Tax Margin | -11.6% | -48.7% | -21.5% | 10.2% | 41.4% |
| Income Tax Expense | 605K | 0 | 0 | 881K | (245.2M) |
| Net Income | (17.91M) | (58.57M) | (25.09M) | 17.49M | 367.02M |
| Net Margin | -12.0% | -48.7% | -21.5% | 9.8% | 124.7% |
| EPS (Basic) | (1.10) | (3.40) | (1.44) | 0.99 | 20.40 |
| EPS (Diluted) | (1.10) | (3.40) | (1.44) | 0.99 | 19.48 |
| Weighted Avg Shares | 17.05M | 17.24M | 17.4M | 17.58M | 17.99M |
| Weighted Avg Shares (Diluted) | 17.05M | 17.24M | 17.4M | 17.69M | 18.84M |
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
Intrinsic Alpha fair value
Locked
Current Price
$42.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.